Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Inclusion Criteria: * peripheral T cell lymphoma (PTCL); * no remission or relapse after at least one previous systemic treatment； * at least one assessable lesion； * 18-75 years; * ECOG PS 0-2; * proper functioning of the major organs; * expected survival time ≥3 months. Exclusion Criteria: * previous received treatment of HDAC inhibitor or lenalidomide; * central nervous system (CNS) involvement; * serious heart problems; * known allergies to experimental drug ingredients; * diagnosed with or receiving treatment for a malignancy other than lymphoma; * uncontrolled active infection, with the exception of tumor-related b-symptom fever; * unable or unwilling to receive antithrombotic therapy; * history of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 12 months;